Search Clinical Trials in the European Union

Duration
≤5 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 525 trials

HPV Infections: 2LPAPI® Treatment Study

We are testing a new treatment, 2LPAPI®, for people with high-risk HPV infections to see if it helps clear the virus better than a placebo. The study also looks at safety and how the treatment affects cervical cell health.

Human Papillomavirus Infection>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesGynecology and ObstetricsInfectious Diseases

Rotator Cuff Disease: Botulinum Toxin Treatment

We are studying whether botulinum toxin can help reduce pain and improve function in people with degenerative rotator cuff disease. Participants will be monitored for effectiveness and any side effects over three months.

Shoulder Tendonitis>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesOrthopedics and Traumatology

Intracerebral Hemorrhage: Anticoagulation Strategies

We are studying whether avoiding anticoagulation or using a specific procedure helps improve health outcomes for patients after an intracerebral hemorrhage. We also aim to identify brain markers that may indicate future bleeding risks.

Cerebral Hemorrhage1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Multiple Myeloma: Teclistamab with Daratumumab or Lenalidomide

We are studying the effectiveness and safety of a new treatment combination for elderly patients with newly diagnosed multiple myeloma. This research aims to find better ways to manage the disease.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Hemorrhoidal Disease: RAFAELO® Procedure with Pain Management

We are studying whether adding perianal infiltration during the RAFAELO® procedure helps reduce pain after treatment for hemorrhoids. This trial aims to improve comfort for patients undergoing this procedure.

Hemorrhoids>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Non-Small Cell Lung Cancer: 68GaNOTA-Anti-MMR Imaging Study

We are testing a new imaging agent to see how well it can identify certain immune cells in patients with non-small cell lung cancer. This may help improve imaging techniques for better diagnosis and treatment planning.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngologyPulmonology

Multiple Myeloma: Elranatamab Combination Therapy

We are studying a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to see if it works better than a standard treatment option.

Multiple Myeloma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Metycor Study for Autonomous Cortisol Secretion

We are testing a new treatment to see if it improves blood pressure, glucose levels, and overall health in patients with autonomous cortisol secretion. The study also looks at effects on weight, bone health, and quality of life.

Mild Autonomous Cortisol Secretion6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Yellow Fever Vaccination: Comparing Injection Methods

We are studying how different ways of giving the yellow fever vaccine affect the immune response in participants. This trial aims to find out which method may provide better protection and safety.

Yellow Fever3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Advanced Melanoma: Enfortumab Vedotin with Pembrolizumab

We are studying a combination of two treatments for patients with advanced melanoma who have been previously treated. The goal is to see if this combination is effective and safe for improving patient outcomes.

Metastatic MelanomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

HER2+ Metastatic Colorectal Cancer: Tucatinib Combination Study

We are investigating whether a new treatment combining tucatinib, trastuzumab, and mFOLFOX6 can improve outcomes for patients with HER2+ metastatic colorectal cancer compared to standard care.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Clear Cell Renal Cell Carcinoma: PET Scan Comparison

We are comparing two different PET scans to see which one detects tumors better in patients with clear cell renal cell carcinoma. This study may help improve diagnosis for those suspected of having this type of cancer.

Metastatic Renal Cell Carcinoma≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Dent 2 Disease: Alpelisib Study

We are testing the medication alpelisib in patients with Dent 2 disease to see if it improves kidney function and is safe to use. This study will help us understand its potential benefits for kidney health.

Dent's DiseaseEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrologyUrology

EBV Infection: Testing 2LEBV® and 2LXFS® for Fatigue

We are studying whether two new treatments can help reduce fatigue in patients with an EBV infection compared to a placebo. The trial also looks at other symptoms and safety.

Epstein-Barr Virus Infection>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesInfectious Diseases

Mixed Dyslipidaemia: Rosuvastatin and Fenofibrate Study

We are comparing two medication combinations to see which one better lowers bad cholesterol in patients with mixed dyslipidaemia at high risk for heart disease. This study will help us understand their effectiveness and safety.

Dyslipidemia3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology

Vaginal Atrophy: New Estriol Vaginal Ring

We are testing a new vaginal ring that releases estriol to see if it improves vaginal health in postmenopausal women. The study will measure changes in vaginal tissue and pH after treatment.

Vulvovaginal Atrophy≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Preventing Chemotherapy-Induced Nausea in Children: IV NEPA Study

We are studying a new intravenous treatment for children with cancer to see if it can effectively prevent nausea and vomiting during chemotherapy. This trial compares IV NEPA with standard treatments to ensure safety and effectiveness.

Chemotherapy-Induced Nausea and Vomiting3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncologyPediatrics

Ocular Melanoma: Roginolisib Treatment Study

We are studying the effectiveness of roginolisib for patients with advanced ocular or uveal melanoma compared to standard therapies. The trial will also assess safety and quality of life impacts.

Uveal MelanomaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

Idiopathic Retroperitoneal Fibrosis: Early Steroid Discontinuation Study

We are investigating whether stopping steroid treatment early in patients with idiopathic retroperitoneal fibrosis affects relapse rates. This study aims to improve treatment strategies for managing this condition.

Idiopathic Retroperitoneal Fibrosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

PBP1510 for Advanced Pancreatic Cancer

We are studying a new treatment called PBP1510 in patients with advanced pancreatic cancer that has not responded to previous chemotherapy. The trial will evaluate its safety and effectiveness, both alone and with another drug, gemcitabine.

Advanced Pancreatic CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology